l e t t e r s Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic gliomas. We also performed targeted mutational analysis of an additional 24 such tumors and genome-wide methylation profiling of 45 gliomas. This study led to the discovery of tumor-specific mutations in PPM1D, encoding wild-type p53-induced protein phosphatase 1D (WIP1), in 37.5% of the BSGs that harbored hallmark H3F3A mutations encoding p.Lys27Met substitutions. PPM1D mutations were mutually exclusive with TP53 mutations in BSG and attenuated p53 activation in vitro. PPM1D mutations were truncating alterations in exon 6 that enhanced the ability of PPM1D to suppress the activation of the DNA damage response checkpoint protein CHK2. These results define PPM1D as a frequent target of somatic mutation and as a potential therapeutic target in brainstem gliomas.
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We explored the genetic landscape of gliomas arising in well-defined locations throughout the brainstem and thalamus, in both children and adults (Supplementary Table 1 ). Whole-exome sequencing was performed on 14 BSGs and 12 thalamic gliomas and matched normal blood samples (Online Methods). The fraction of bases in targeted regions with at least ten reads ranged from 87% to 96% for all the samples ( Supplementary Table 2 ). A total of 708 tumor-specific (somatic) mutations were identified in these 26 samples (an average of 27 mutations per sample; Supplementary Tables 3 and 4) . We validated 81 of 91 randomly selected mutated genes by Sanger sequencing, reflecting a sensitivity of 89% for our whole-exome sequencing (Supplementary Table 5 ).
The mutational landscape of the 14 BSG and 12 thalamic glioma samples is displayed in Figure 1 . Our analysis confirmed that TP53 and H3F3A were frequently mutated in both BSGs and thalamic gliomas (>64% of both tumor types) [1] [2] [3] . In addition, we confirmed the occurrence of PDGFRA alterations in these tumor types, with mutations in this gene identified in one BSG and two thalamic gliomas 4 . Also, an FGFR1 mutation encoding p.Asn546Lys that frequently occurs in pilocytic astrocytomas was identified in one each of the BSGs and thalamic gliomas, with each of these tumors also containing an inactivating NF1 mutation 5 . Sanger sequencing for an additional eight samples identified two FGFR1 mutations encoding p.Val664Leu substitutions in BSG. In total, the occurrence of mutations in FGFR1 in 4 of 34 samples (12%) indicates that these mutations are frequent in BSGs and thalamic gliomas. Most notably, this exome sequencing analysis led to the discovery of mutations in genes that had not previously been linked to these diseases. We also found PPM1D mutations in four BSGs (29%) and IDH1 mutations in five BSGs (36%). All the recurrent mutations in these frequently mutated genes were validated by Sanger sequencing.
To establish the prevalence of recurrent mutations in PPM1D in BSG and to explore the relationship between PPM1D mutations and other alterations, we performed targeted sequencing on an additional 24 BSGs and thalamic gliomas. Sanger sequencing was performed on PPM1D, IDH1, TP53 and H3F3A for a total of 33 BSGs and 17 thalamic gliomas, when including samples used for exomic sequencing (Fig. 2) . Among the extended series of 33 BSGs, 19 samples contained TP53 mutations, 16 samples contained H3F3A mutations, 8 samples contained IDH1 mutations and 6 samples contained PPM1D mutations. In the extended series of 17 thalamic gliomas, we found 13 samples with TP53 mutations and 11 samples with H3F3A mutations. All 27 H3F3A mutations in both BSG and thalamic glioma were the hallmark hotspot mutations encoding p.Lys27Met associated with these midline tumor types 2, 3 . No HIST1H3B mutations and no H3F3A mutations affecting Arg34, which are associated with supratentorial gliomas, were identified 1-3 . PPM1D mutations, as well as IDH1 mutations, were completely absent in thalamic gliomas. Individuals with IDH1-mutated tumors were significantly older at diagnosis than those who had tumors with wild-type IDH1 (median age of 43 l e t t e r s versus 24 years; P = 0.0056), but H3F3A, TP53 and PPM1D mutational status did not delineate significant differences in subject age (Supplementary Table 6 ).
In analysis of the extended series of tumors, PPM1D mutations were only present in the subgroup of H3F3A-mutated BSGs (16/33 BSGs). Almost all H3F3A-mutated BSGs (15/16) contained either a PPM1D mutation or a TP53 mutation in a completely mutually exclusive fashion (Fisher's exact test, P < 1 × 10 −5 ). Overall survival rates were not significantly different for individuals with TP53-mutated and PPM1D-mutated brainstem gliomas (P = 0.15; Supplementary Fig. 1 and Supplementary Table 7 ). This mutual exclusivity and the similar clinical features of the affected subjects suggest that TP53 and PPM1D mutations might have equivalent oncogenic functions in BSG. An additional PPM1D mutation was identified in 1 of 57 cerebral gliomas, indicating that PPM1D mutations are uncommon events in gliomas arising outside the brainstem.
All PPM1D mutations identified here were truncating mutations in exon 6. Six of the PPM1D mutations were nonsense mutations targeting Glu472, Leu484, Ser516, Glu525 (two cases) and Glu540, whereas one was a frameshift mutation that disrupted Asn448 and resulted in a de novo stop codon ( Fig. 3a) . Thus, all PPM1D mutations we identified truncated the C-terminal regulatory domain but left the N-terminal catalytic PP2C phosphatase domain (residues 1-370) intact. PPM1D is a known oncogene that is amplified in breast and other cancers 6 . Also, remarkably similar truncating mutations in exon 6 of PPM1D have emerged recently as an unusual genetic risk factor for cancer after their discovery in germline tissues from rare individuals (<1%) with breast, ovarian or colorectal cancer 7, 8 . Additionally, both gain-of-function PPM1D genetic alternations and inactivating, missense PPM1D mutations were found at low frequency in several types of cancer in available cancer data sets 9 . The PPM1D mutations uncovered here establish truncating mutation in exon 6 of PPM1D as a frequent, tumor-specific (somatic) event in a particular cancer type. To determine whether PPM1D mutations were associated with different PPM1D protein expression patterns in tumors, we performed immunohistochemical analysis of PPM1D protein in a series of BSG tissues. No degradation or increased expression of PPM1D was found in PPM1D-mutated tumors compared to tumors with wild-type PPM1D (Fig. 3b) .
Our targeted sequencing analysis also identified a subgroup of BSGs with IDH1 mutations (8/33; 24%). All IDH1 mutations in BSGs were the hotspot mutations affecting Arg132 that are a hallmark of the npg l e t t e r s supratentorial intermediate-grade gliomas that occur in adults 10 . In BSGs, IDH1 mutations were mutually exclusive with H3F3A mutations (Fisher's exact test, P < 1 × 10 −6 ). Also, IDH1 mutations occurred solely in adult cases (median age of 43 years at diagnosis), which might explain why previous studies that focused solely on pediatric BSG cases did not identify IDH1 alterations 2,3 . Our series of BSGs may have had different characteristics than the series in previous studies because we examined the exophytic portions of diffuse intrinsic gliomas that were accessible for surgical resection, whereas previous studies examined intrinsic tissue from diffuse intrinsic gliomas that might not have had associated exophytic portions 2,3 . We further determined whether BSGs or thalamic gliomas exhibited epigenetic differences from supratentorial gliomas. To do this, we determined the methylation status of >485,000 genomic loci for BSG (n = 17), thalamic glioma (n = 10) and supratentorial glioma (n = 18) samples. These samples were then subjected to unsupervised hierarchical clustering, consensus clustering and principalcomponent analysis based on methylation β values for the 2% most variant loci ( Fig. 4  and Supplementary Figs. 2 and 3) . Tumor location did not affect clustering of the samples when using these approaches. Rather, these clustering approaches identified three distinct groups corresponding almost perfectly to IDH1 and H3F3A mutation status. IDH1-mutated tumors tended to be hypermethylated compared to tumors with 
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Heterozygous Figure 4 Heat map of variant methylation probes in 45 glioma samples, with genetic information. Forty-five glioma samples (columns) and the top 2% of variant probes (rows) were arranged by unsupervised averagelinkage hierarchical clustering. IDH1-mutated, H3F3A-mutated (Lys27) and wild-type samples clustered separately. Within the IDH1-mutated subcluster, two samples with hemizygous IDH1 mutation described previously 23 were included (marked in light green for IDH1 mutation status), which showed distinct methylation patterns compared with other IDH1-mutated samples. Gene expression-based classification into proneural, neural, classical and mesenchymal subtypes by The Cancer Genome Atlas (TCGA) classification 24 is shown for samples for which material was available for gene expression analysis. l e t t e r s wild-type IDH1, regardless of whether they were located in the brainstem or supratentorium, whereas H3F3A-mutated tumors showed a hypomethylation phenotype (Supplementary Figs. 4 and 5) , consistent with previous reports [11] [12] [13] [14] . Notably, samples with wild-type and mutated PPM1D were intermingled within the cluster with H3F3Amutated tumors. Gene expression data for selected samples were analyzed by gene set enrichment analysis (GSEA) 15, 16 ( Supplementary  Table 8 ). This analysis confirmed the association between IDH1 mutation, H3F3A mutation and methylation status [11] [12] [13] [14] and indicated that tumor location and PPM1D mutation status are not major contributors to tumor methylation status. We next sought to examine the functional consequences of the PPM1D mutations identified in our genome-wide mutational analysis of BSGs, especially in the context of radiation treatment, a key therapeutic modality for gliomas. PPM1D functions as a phosphatase that dephosphorylates and inactivates many DNA damage response mediators such as CHK2, p53 and H2AX [17] [18] [19] . Cancer-associated PPM1D truncation mutants attenuate p53 and H2AX activation following irradiation, possibly because these PPM1D mutants are stabilized at the protein level owing to loss of a C-terminal degradation signal 8 . To extend these findings, we assessed the impact of truncated PPM1D on p53, H2AX and CHK2 activation and examined the effect of repairing PPM1D mutation in a cell line with a native PPM1D mutation.
The glioma-derived Glu472* and Glu540* truncated PPM1D mutants were introduced into HEK293T cells, which have wild-type TP53. As controls, we also introduced wild-type PPM1D, a phosphatasedead Asp314Ala PPM1D mutant 20 or vector alone. Expression of the glioma-derived PPM1D mutants attenuated increases in the levels of phosphorylation of CHK2 at Thr68, phosphorylation of p53 at Ser15 and γH2AX following 10 Gy of irradiation (Fig. 5a) . This effect was also achieved by expressing wild-type PPM1D but not the phosphatase-dead Asp314Ala PPM1D mutant. These results demonstrate that cancer-associated PPM1D truncation mutants retain phosphatase activity against CHK2 and confirm that they retain phosphatase activity against p53 and H2AX 7,8 .
We next sought to dissect the contribution of PPM1D mutation to the biochemical and biological properties of PPM1D-mutated cancer cells. Because BSG-derived cell lines with PPM1D mutation have not been Figure 5 Effect of cancer-derived truncated PPM1D on CHK2, p53 and H2AX activation and cell growth. (a) HEK293T cells transfected with full-length wild-type (WT) PPM1D, Glu472* truncated PPM1D, Glu540* truncated PPM1D and Asp314Ala PPM1D were exposed to ionizing radiation (IR; 10 Gy). Cells were collected before ionizing radiation and 1 and 5 h after ionizing radiation. Whole-cell lysates were analyzed for phosphorylation of CHK2 at Thr68 (pT68), phosphorylation of p53 at Ser15 (pS15), γH2AX and GAPDH. Protein blotting for PPM1D showed successful transfection.
(b) Gene targeting to repair a native PPM1D mutation. HCT116 cells encode a heterozygous frameshift deletion that results in a truncated PPM1D mutant (Leu450*). Homologous recombination was used to replace the mutated PPM1D allele with wild-type PPM1D in two HCT116 sublines. Protein blotting demonstrates expression of full-length and truncated PPM1D in the parental cell line but only full-length PPM1D expression in the two repaired cell lines. PPM1D-F, full-length PPM1D; PPM1D-T, truncated PPM1D. (c) The parental HCT116 line (PPM1D mutant) and two isogenic repaired lines (PPM1D wild type) were exposed to ionizing radiation (10 Gy). Cells were collected before ionizing radiation and 1 and 5 h after ionizing radiation. Whole-cell lysates were analyzed for phosphorylation of CHK2 at Thr68, phosphorylation of p53 at Ser15, γH2AX and GAPDH. (d) Proliferation assay for the HCT116 parental cell line (PPM1D mutant) and the isogenic repaired lines (PPM1D wild type). We seeded 1,000 cells in each well of a 96-well plate (in triplicate) on day 0. Relative cell number was determined each day after seeding. Data are represented as means ± s.e.m. (e) Colony formation by the PPM1D-mutant HCT116 parental cell line and isogenic lines with wild-type PPM1D. Colony formation was assessed in the absence of ionizing radiation and under 2 Gy or 4 Gy of ionizing radiation. *P < 0.05 in comparison of parental cells and isogenic repaired line 1 or 2 under 0, 2 and 4 Gy of ionizing radiation. n = 4 technical replicates; data are represented as means ± s.e.m.
npg established, we focused on the HCT116 colorectal carcinoma cell line that contains a native PPM1D mutation encoding p.Leu450* (ref. 8) in the same region as the mutations identified in BSGs. Using homologous recombination (Online Methods), we repaired the mutated PPM1D allele to create two isogenic cell lines with wild-type PPM1D ( Fig. 5b  and Supplementary Fig. 6 ). After irradiation, the repaired cell lines with wild-type PPM1D had higher levels of CHK2 and p53 phosphorylation than the PPM1D-mutant parental cell line (Fig. 5c) . γH2AX levels were not increased by replacement of the mutant PPM1D allele, indicating that dynamic H2AX phosphorylation might be regulated by other phosphatases in this cell line. Notably, cell growth and colony formation were decreased after repair of the mutant PPM1D allele (Fig. 5d,e and Supplementary Fig. 7) , indicating that mutant PPM1D drives the growth of PPM1D-mutated cancer cells. These results demonstrate that mutant PPM1D contributes to cell growth, as well as to p53 and CHK2 dephosphorylation, after radiation treatment.
In summary, our genomic and epigenomic analyses identify H3F3A-PPM1D co-mutation and IDH1-TP53 co-mutation as representative of common genetic subtypes of BSGs and confirm that H3F3A-TP53 co-mutation commonly occurs in both BSGs and thalamic gliomas. We identified truncating mutations in exon 6 of PPM1D as frequent somatic events in a human tumor type, finding the typical tumorspecific distribution expected for oncogenic mutations selected during the clonal evolution of tumors. The mutual exclusivity of PPM1D and TP53 mutations together with the results from our functional study suggest that somatic mutations in either PPM1D or TP53 are the genetic basis for dysfunction of the radiation-induced DNA damage response network in brainstem gliomas. Our data further show that the encoded gain-of-function PPM1D mutants can suppress phosphorylation of CHK2 upon radiation-induced DNA damage stress and potentially abrogate cell cycle checkpoints.
This study adds another layer to the complex genetic role for PPM1D in cancer: in addition to the gain-of-function and truncating PPM1D mutations reported here in BSGs, germline mosaic gain-of-function and truncating PPM1D mutations have been linked to several other types of cancer 7, 8 , and still other rare tumors have been reported with loss-of-function and missense PPM1D mutations 9 . Assessment of PPM1D mutational status in future prospective trials will be necessary to determine whether PPM1D status is predictive of response to radiation or other therapies. Future studies that employ whole-genome sequencing may identify additional alterations in these tumor types, and further studies on genetically engineered models of PPM1D-mutated gliomas, which have yet to be developed, will determine the precise mechanism by which PPM1D mutations confer a selective advantage in the glioma setting. Also, as small chemical inhibitors of PPM1D phosphatase activity are being explored 21, 22 , the finding of gain-offunction PPM1D mutations offers a potential therapeutic opportunity for a subgroup of patients with this challenging brain tumor type.
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